Neuregulin 4 Levels Fall in Type 2 Diabetes

A study of 302 adults links lower serum Neuregulin 4 to type 2 diabetes and to more severe diabetic retinopathy.

Updated on Nov. 19, 2026 in Diabetes

Isometric editorial illustration of an amber glass vial beside pale spheres on a plain slate surface, evoking a laboratory biomarker measurement.
Researchers found lower serum Neuregulin 4 levels in 224 adults with type 2 diabetes, with levels falling further as diabetic retinopathy worsened. AI Illustration. Upload story photo >

Researchers measured serum Neuregulin 4 in 302 adults, including 78 healthy controls and 224 patients with type 2 diabetes, and found lower levels in the diabetic group. The study was published as an accepted early-access article on November 19, 2026.

Why it matters

The findings suggest Neuregulin 4 may be a marker associated with both type 2 diabetes and the progression of diabetic retinopathy, a leading cause of vision loss. Further research would be needed to determine whether it has any clinical value for diagnosis or monitoring.

The study, measuring serum biomarkers in 302 adults, reported an odds ratio of 0.376 (95% CI 0.196-0.702) for lower diabetic retinopathy risk at Neuregulin 4 levels above 3.695 ng/ml. It remains unclear from the reported findings whether these associations would hold in larger or more diverse populations.

The details

Researchers assayed serum Neuregulin 4 by enzyme-linked immunosorbent assay and evaluated diabetic retinopathy using optical coherence tomography angiography. Levels were lower in the type 2 diabetes group than in controls, and they decreased further as retinopathy severity increased, with higher fasting insulin and high-sensitivity C-reactive protein also linked to diabetes risk.

Timeline

  1. November 19, 2026: Study published as an accepted early-access article.

Health Landscape

The study adds a candidate serum marker to the existing approach of grading diabetic retinopathy through retinal imaging, such as the severity scales used by the Diabetic Retinopathy Clinical Research Network. Its contribution is to show that circulating levels move in step with retinopathy stage, a question that remains open for clinical use.

For people living with type 2 diabetes, the study does not change current screening or treatment, since Neuregulin 4 is not yet a clinical test. Anyone with diabetes should continue routine eye examinations, which remain the established way to detect retinopathy early.

The takeaway

Regular diabetic eye exams remain the standard way to catch retinopathy early, and people with diabetes should keep scheduling them. Research on biomarkers like Neuregulin 4 is still at an early stage.

Further reading

Explore more in the Diabetes section for context on how the disease is studied and managed.

Source note: This article includes information reported by Nature.